ChemoCentryx banks $25m as GSK takes on RA compound
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has exercised a second option to license a drug that has been developed in its collaboration with ChemoCentryx, a California biotech firm focused on oral therapeutics targeting chemokine and chemoattractant systems. GSK's decision to take an exclusive licence on CCX354, following recently announced positive Phase II results in rheumatoid arthritis, triggers a $25 million payment to ChemoCentryx.